Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Hua Medicine (Shanghai) Ltd. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct art units, reflecting a spread across different examination specialties. The portfolio involves distinct examiners, each currently reviewing a pending matter. This distribution suggests that the company's current patent activity is divided between different technical focuses within the broader Biotechnology & Pharmaceuticals field.
CHI, AMANDA LYNN serves as the busiest examiner for this portfolio, overseeing 1 pending office action. With 2 pending office actions distributed among 2 distinct art units, the prosecution strategy must account for the specific preferences of the assigned personnel. This structure requires a coordinated approach to ensure that arguments remain consistent across different administrative groups. Practitioners should leverage the feedback from the distinct examiners to refine their overall approach to patent acquisition in this sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHI, AMANDA LYNN | 1 | — | — |
| MURESAN, ANA Z | 1 | 75.0% | +31.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042901 | PREPARATION OF SUBSTITUTED ACRYLATE COMPOUND | MURESAN, ANA Z | 56d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042901 | PREPARATION OF SUBSTITUTED ACRYLATE COMPOUND | MURESAN, ANA Z | 56d overdue |
| Art Unit | Apps |
|---|---|
| 1600 | 1 |
| 1692 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18610100 | PHARMACEUTICAL COMBINATION, COMPOSITION AND COMPOUND PREPARATION COMPRISING GLUCOKINASE ACTIVATOR AND DPP-IV INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | CHI, AMANDA LYNN | 1600 | §103Other | Final Rejection | — | Pending | Mar 19, 2024 |
| 18042901 | PREPARATION OF SUBSTITUTED ACRYLATE COMPOUND | MURESAN, ANA Z | 1692 | §102§112 | Non-Final OA | 56d overdue | Pending | Feb 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial